Journal
ANNUAL REVIEW OF CANCER BIOLOGY
Volume 6, Issue -, Pages 85-102Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-cancerbio-070220-111016
Keywords
interferon-gamma; major histocompatibility complex; JAK; immunoresistance; checkpoint inhibitors; tumor microenvironment
Categories
Funding
- German Cancer Aid organization (Deutsche Krebshilfe) [111546, 70113455]
- German Research Foundation (Deutsche Forschungsgemeinschaft) [PA 2376/1-1]
- research foundation Hiege-Stiftung gegen Hautkrebs
- Fundacion Cientifica AECC (Asociacion Espanola Contra el Cancer)
- Fundacion La Caixa
- Mark Foundation
- Fundacion BBVA
- CIBERONC (Consorcio Centro de Investigacion Biomedica en Red de Cancer)
- Parker Institute for Cancer Immunotherapy
- National Institutes of Health (NIH) [R35 CA197633, P01 CA244118, P30 CA016042]
- Ressler Family Fund
- Ken and Donna Schultz Fund
Ask authors/readers for more resources
Resistance to immunotherapy is often caused by acquired stealth mechanisms of tumor cells, such as loss of MHC class I expression or downregulation of antigen presentation pathways. Mutations in molecules involved in interferon-gamma signaling lead to unresponsiveness to IFN gamma and loss of recognition and killing by cytotoxic T lymphocytes. However, this mechanism also increases the sensitivity of tumor cells to natural killer cells, which could be exploited to overcome resistance.
Resistance to immunotherapy is due in some instances to the acquired stealth mechanisms of tumor cells that lose expression of MHC class I antigen- presenting molecules or downregulate their class I antigen-presentation pathways. Most dramatically, biallelic beta 2-microglobulin (B2M) loss leads to complete loss of MHC class I expression and to invisibility to CD8(+) T cells. MHC class I expression and antigen presentation are potently up- regulated by interferon-gamma (IFN gamma) in a manner that depends on IFN gamma receptor (IFNGR) signaling via JAK1 and JAK2. Mutations in these molecules lead to IFN gamma unresponsiveness and mediate loss of recognition and killing by cytotoxic T lymphocytes. Loss of MHC class I augments sensitivity of tumor cells to be killed by natural killer (NK) lymphocytes, and this mechanism could be exploited to revert resistance, for instance, with interleukin-2 (IL-2)-based agents. Moreover, in some experimental models, potent local type I interferon responses, such as those following intratumoral injection of Toll-like receptor 9 (TLR9) or TLR3 agonists, revert resistance due to mutations of JAKs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available